REVENUE (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Net Revenue

The following table reflects total revenue, net for the three and nine months ended September 30, 2023 and 2022 (in thousands): 

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Product sales, net:
INDOCIN products	$	17,948	$	21,869	$	76,369	$	66,067
ROLVEDON	7,132		—		7,132		—
Otrexup	2,807		3,004		9,222		8,699
Sympazan	2,103		—		7,232		—
SPRIX	2,545		2,455		6,807		6,437
CAMBIA	1,993		5,808		6,062		17,464
Zipsor	597		259		2,751		2,704
Other products	12		884		1,414		3,887
Total product sales, net	35,137		34,279		116,989		105,258
Royalties and milestone revenue	490		473		1,910		1,916
Other revenue	—		(540)		185		(1,290)
Total revenues	$	35,627	$	34,212	$	119,084	$	105,884